

The  
United  
States  
of  
America



**The Director of the United States  
Patent and Trademark Office**

*Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this*

**United States Patent**

*Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.*

*If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.*

*If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extensions.*

*Jon W. Dudas*

Acting Director of the United States Patent and Trademark Office



US006689353B1

(12) **United States Patent**  
**Wang et al.**

(10) **Patent No.:** **US 6,689,353 B1**  
(45) **Date of Patent:** **Feb. 10, 2004**

(54) **STABILIZED INTERLEUKIN 2**

- (75) Inventors: **Wei Wang**, Alameda, CA (US); **Rajiv Nayar**, Richmond, CA (US); **Michael A. Shearer**, Fairfield, CA (US)
- (73) Assignee: **Bayer Pharmaceuticals Corporation**, West Haven, CT (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 248 days.

(21) Appl. No.: **09/605,577**

(22) Filed: **Jun. 28, 2000**

(51) Int. Cl.<sup>7</sup> ..... **A61K 38/20**; **A61K 38/00**

(52) U.S. Cl. .... **424/85.2**; **424/85.1**; **514/2**;  
514/8; **514/12**

(58) Field of Search ..... **514/2**, **8**, **12**; **424/85.1**,  
424/85.2

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

- 4,645,830 A \* 2/1987 Yasushi et al. .... 435/69.52  
5,358,708 A 10/1994 Patel  
5,656,730 A \* 8/1997 Lee ..... 530/357.3  
5,763,401 A 6/1998 Nayar  
6,267,958 B1 \* 7/2001 Andya et al. .... 424/130.1

**FOREIGN PATENT DOCUMENTS**

WO WO-996018 A1 \* 11/1999 ..... C12N/15/26

**OTHER PUBLICATIONS**

Taneja et al., Increased thermal stability of proteins in the presence of amino acids, (1994) *Biochem Journal*, vol:303, 147-153.\*

Rishi et al., Role of non-compatible osmolytes in the stabilization of proteins during heat stress, (1998) *Biochem Journal*, vol:329, 137-143.\*

Pikal, M. J., *Freeze-Drying of Proteins, PartII: Formulation Selection* (1990), Biopharm, Vol 3, No. 9, pp 26-30.\*

Chang, B. S. et al, Development of an Efficient Single Step Freeze-Drying Cycle for Protein Formulations, *Pharm. Res.*, Vol 12, No. 6 pp 831-837 (1995), Plenum Publ. Corp.

Wang, W., Lyophilization and Development of Solid Protein Pharmaceuticals, *International Journal of Pharmaceutics*, 203:1-60, 2000.

\* cited by examiner

*Primary Examiner*—Gary Kunz

*Assistant Examiner*—Jegatheesan Sheharaseyon

(74) *Attorney, Agent, or Firm*—John W. Mahoney

(57) **ABSTRACT**

A stable pharmaceutical preparation comprising Human interleukin-2 or a variant thereof and a stabilizing amount of histidine. A preferred formulation includes glycine and sucrose and a variant of IL-2 having a single mutation, N88R. The preferred formulation is in lyophilized form which, on reconstitution with an aqueous diluent, results in a solution having a pH ranging from about 5.0 to 6.5.

**6 Claims, 2 Drawing Sheets**